Physician profile
Arthur Walczyk
NPI 1003800723
$3,917.00
in general payments reported to CMS, 2019-2025
27 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $563 · 2021: $256 · 2022: $281 · 2023: $390 · 2024: $534 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $741.96 | 2019-2024 | Trulance, Plenvu, Xifaxan |
| Abbvie INC. | $518.02 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Pfizer INC. | $512.27 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $357.44 | 2019-2025 | |
| Genzyme Corporation | $292.25 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.47 | 2019-2022 | |
| Braintree Laboratories, INC. | $194.35 | 2019-2022 | |
| Janssen Biotech, INC. | $182.06 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $119.04 | 2019-2021 | |
| Gilead Sciences, INC. | $117.08 | 2019-2023 | |
| Allergan, INC. | $110.30 | 2019-2020 | |
| Ardelyx, INC. | $81.19 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $68.01 | 2024 | Cre Pro, Resolution 360 Clip |
| Ironwood Pharmaceuticals, INC | $54.40 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $39.79 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $38.16 | 2019-2025 | Sucraid |
| Celgene Corporation | $31.66 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $31.31 | 2025 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $26.15 | 2024 | Lesionhunter |
| Regeneron Healthcare Solutions, INC. | $24.33 | 2023 | Dupixent |
| Olympus America INC. | $23.92 | 2025 | Single Use Repositionable Clip |
| Aimmune Therapeutics, INC. | $22.71 | 2024 | |
| Novo Nordisk INC | $17.79 | 2025 | Wegovy |
| Ucb, INC. | $17.15 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.33 | 2023 | |
| Axonics, INC. | $14.60 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Walczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.